Xilio Therapeutics, Inc. (XLO)
8.94
+0.03
(+0.34%)
USD |
NASDAQ |
Sep 09, 15:06
Xilio Therapeutics EPS Diluted (Quarterly) : -0.3284 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3284 |
| March 31, 2026 | -0.5829 |
| December 31, 2025 | 0.8077 |
| September 30, 2025 | -1.582 |
| June 30, 2025 | -2.300 |
| March 31, 2025 | -0.1776 |
| December 31, 2024 | -2.834 |
| September 30, 2024 | -0.2209 |
| June 30, 2024 | -0.2411 |
| March 31, 2024 | -0.6163 |
| December 31, 2023 | -0.6407 |
| September 30, 2023 | -0.6085 |
| June 30, 2023 | -0.7046 |
| Date | Value |
|---|---|
| March 31, 2023 | -0.8255 |
| December 31, 2022 | -0.8194 |
| September 30, 2022 | -0.7223 |
| June 30, 2022 | -0.8988 |
| March 31, 2022 | -0.7802 |
| December 31, 2021 | -0.7201 |
| September 30, 2021 | -0.5916 |
| June 30, 2021 | -0.8439 |
| March 31, 2021 | -0.6068 |
| December 31, 2020 | -10.59 |
| September 30, 2020 | -0.5395 |
| June 30, 2020 | -0.419 |
| March 31, 2020 | -0.2955 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cue Biopharma, Inc. | -24.14 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.373M |
| Revenue (Quarterly) | 18.69M |
| Total Expenses (Quarterly) | 25.06M |
| Enterprise Value | -71.11M |
| Gross Profit Margin (Quarterly) | 98.23% |
| Profit Margin (Quarterly) | -34.09% |
| Earnings Yield | -18.86% |
| Normalized Earnings Yield | -20.14 |